|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administration_site
|
thigh
abdominal area
|
|
gptkbp:class
|
gptkb:Hirogen
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
gptkb:endometriosis
precocious puberty
uterine fibroids
hormone-sensitive cancers
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
hypersensitivity to leuprolide
|
|
gptkbp:dosage_form
|
injection
|
|
gptkbp:duration
|
monthly
|
|
gptkbp:effective_date
|
gptkb:2000
|
|
gptkbp:financial_support
|
avoid alcohol
report any unusual bleeding
monitor for signs of adrenal insufficiency
consult doctor before starting new medications
|
|
gptkbp:form
|
injectable solution
|
|
gptkbp:healthcare
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eligard
|
|
gptkbp:ingredients
|
gptkb:leuprolide_acetate
|
|
gptkbp:interacts_with
|
anticoagulants
other hormonal therapies
|
|
gptkbp:invention
|
patented
|
|
gptkbp:manufacturer
|
gptkb:Astra_Zeneca
|
|
gptkbp:marketed_as
|
gptkb:Eligard_22.5_mg
gptkb:Eligard_30_mg
gptkb:Eligard_45_mg
gptkb:Eligard_7.5_mg
|
|
gptkbp:mechanism_of_action
|
hormonal therapy
|
|
gptkbp:packaging
|
single-dose vial
|
|
gptkbp:patient_population
|
adult males
adult females
|
|
gptkbp:previous_name
|
no
|
|
gptkbp:price
|
varies by pharmacy
|
|
gptkbp:requires
|
gptkb:true
|
|
gptkbp:research
|
clinical trials
off-label uses
|
|
gptkbp:route_of_administration
|
subcutaneous injection
|
|
gptkbp:safety_measures
|
regular blood tests
monitoring for bone density loss
monitoring for cardiovascular health
monitoring for kidney function
monitoring for liver function
|
|
gptkbp:service_frequency
|
once a month
|
|
gptkbp:side_effect
|
fatigue
nausea
weight gain
hot flashes
decreased libido
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:used_for
|
gptkb:Oncology
|
|
gptkbp:bfsParent
|
gptkb:Zoladex
|
|
gptkbp:bfsLayer
|
5
|